Literature DB >> 15184408

Specific T-cell epitopes for immunoassay-based diagnosis of Mycobacterium tuberculosis infection.

Inger Brock1, Karin Weldingh, Eliane M S Leyten, Sandra M Arend, Pernille Ravn, Peter Andersen.   

Abstract

The currently used method for immunological detection of tuberculosis infection, the tuberculin skin test, has low specificity. Antigens specific for Mycobacterium tuberculosis to replace purified protein derivative are therefore urgently needed. We have performed a rigorous assessment of the diagnostic potential of four recently identified antigens (Rv2653, Rv2654, Rv3873, and Rv3878) from genomic regions that are lacking from the Mycobacterium bovis bacillus Calmette-Guérin (BCG) vaccine strains as well as from the most common nontuberculous mycobacteria. The fine specificity of potential epitopes in these molecules was evaluated by sensitive testing of the T-cell responses of peripheral blood mononuclear cells derived from M. bovis BCG-vaccinated healthy individuals to synthesized overlapping peptides. Three of the four molecules contained regions with significant specificity problems (Rv2653, Rv3873, and Rv3878). We selected and combined the specific peptide stretches from the four proteins not recognized by M. bovis BCG-vaccinated individuals. These peptide stretches were tested with peripheral blood mononuclear cells obtained from patients with microscopy- or culture-confirmed tuberculosis and from healthy M. bovis BCG-vaccinated controls. The combination of the most promising stretches from this analysis showed a sensitivity level (57%) comparable to the level found with the two well-known M. tuberculosis-specific proteins ESAT-6 and CFP-10 (75 and 66%, respectively). The combination of ESAT-6, CFP-10, and the novel specific peptide stretches gave an overall sensitivity of 84% at a specificity of 97%. In a validation experiment with new experimental groups, the sensitivities obtained were 57% for the combination of peptides and 90% for the combination of the peptides, ESAT-6, and CFP-10. This combination gave a specificity of 95%.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15184408      PMCID: PMC427833          DOI: 10.1128/JCM.42.6.2379-2387.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  45 in total

1.  Diagnosis of tuberculosis based on the two specific antigens ESAT-6 and CFP10.

Authors:  L A van Pinxteren; P Ravn; E M Agger; J Pollock; P Andersen
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

2.  Use of ESAT-6 and CFP-10 antigens for diagnosis of extrapulmonary tuberculosis.

Authors:  M E Munk; S M Arend; I Brock; T H Ottenhoff; P Andersen
Journal:  J Infect Dis       Date:  2001-01-01       Impact factor: 5.226

Review 3.  Rapid diagnosis of tuberculosis: laboratory techniques applicable in developing countries.

Authors:  T M Daniel
Journal:  Rev Infect Dis       Date:  1989 Mar-Apr

4.  Use of synthetic peptides derived from the antigens ESAT-6 and CFP-10 for differential diagnosis of bovine tuberculosis in cattle.

Authors:  H M Vordermeier; A Whelan; P J Cockle; L Farrant; N Palmer; R G Hewinson
Journal:  Clin Diagn Lab Immunol       Date:  2001-05

5.  Detection of active tuberculosis infection by T cell responses to early-secreted antigenic target 6-kDa protein and culture filtrate protein 10.

Authors:  S M Arend; P Andersen; K E van Meijgaarden; R L Skjot; Y W Subronto; J T van Dissel; T H Ottenhoff
Journal:  J Infect Dis       Date:  2000-05-15       Impact factor: 5.226

6.  A postgenomic approach to identification of Mycobacterium leprae-specific peptides as T-cell reagents.

Authors:  H M Dockrell; S Brahmbhatt; B D Robertson; S Britton; U Fruth; N Gebre; M Hunegnaw; R Hussain; R Manandhar; L Murillo; M C Pessolani; P Roche; J L Salgado; E Sampaio; F Shahid; J E Thole; D B Young
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

7.  Tuberculin-purified protein derivative-, MPT-64-, and ESAT-6-stimulated gamma interferon responses in medical students before and after Mycobacterium bovis BCG vaccination and in patients with tuberculosis.

Authors:  P D Johnson; R L Stuart; M L Grayson; D Olden; A Clancy; P Ravn; P Andersen; W J Britton; J S Rothel
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

8.  Molecular and immunological characterization of Mycobacterium tuberculosis CFP-10, an immunodiagnostic antigen missing in Mycobacterium bovis BCG.

Authors:  D C Dillon; M R Alderson; C H Day; T Bement; A Campos-Neto; Y A Skeiky; T Vedvick; R Badaro; S G Reed; R Houghton
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

Review 9.  Specific immune-based diagnosis of tuberculosis.

Authors:  P Andersen; M E Munk; J M Pollock; T M Doherty
Journal:  Lancet       Date:  2000-09-23       Impact factor: 79.321

10.  Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells.

Authors:  A Lalvani; A A Pathan; H McShane; R J Wilkinson; M Latif; C P Conlon; G Pasvol; A V Hill
Journal:  Am J Respir Crit Care Med       Date:  2001-03       Impact factor: 21.405

View more
  44 in total

1.  Postgenomic approach to identify novel Mycobacterium leprae antigens with potential to improve immunodiagnosis of infection.

Authors:  Annemieke Geluk; Michèl R Klein; Kees L M C Franken; Krista E van Meijgaarden; Brigitte Wieles; Kelly Cristina Pereira; Samira Bührer-Sékula; Paul R Klatser; Patrick J Brennan; John S Spencer; Diana L Williams; Maria C V Pessolani; Elizabeth P Sampaio; Tom H M Ottenhoff
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

2.  Interferon-gamma release assays in the detection of latent tuberculosis infection in patients with inflammatory arthritis scheduled for anti-tumour necrosis factor treatment.

Authors:  Sonia Mínguez; Irene Latorre; Lourdes Mateo; Alicia Lacoma; Jéssica Diaz; Alejandro Olivé; Jose Domínguez
Journal:  Clin Rheumatol       Date:  2012-01-21       Impact factor: 2.980

3.  Protective efficacy of BCG.

Authors:  Soumya Swaminathan
Journal:  Indian J Pediatr       Date:  2004-12       Impact factor: 1.967

4.  Comparison of two commercially available gamma interferon blood tests for immunodiagnosis of tuberculosis.

Authors:  Jose Domínguez; Juan Ruiz-Manzano; Malú De Souza-Galvão; Irene Latorre; Celia Milà; Silvia Blanco; M Angeles Jiménez; Cristina Prat; Alicia Lacoma; Neus Altet; Vicente Ausina
Journal:  Clin Vaccine Immunol       Date:  2007-10-31

Review 5.  Antigens for CD4 and CD8 T cells in tuberculosis.

Authors:  Cecilia S Lindestam Arlehamn; David Lewinsohn; Alessandro Sette; Deborah Lewinsohn
Journal:  Cold Spring Harb Perspect Med       Date:  2014-05-22       Impact factor: 6.915

Review 6.  Applications for T-cell epitope queries and tools in the Immune Epitope Database and Analysis Resource.

Authors:  Yohan Kim; Alessandro Sette; Bjoern Peters
Journal:  J Immunol Methods       Date:  2010-10-31       Impact factor: 2.303

7.  First-in-man open clinical trial of a combined rdESAT-6 and rCFP-10 tuberculosis specific skin test reagent.

Authors:  Winnie Bergstedt; Pernille N Tingskov; Birgit Thierry-Carstensen; Søren T Hoff; Henrik Aggerbeck; Vibeke O Thomsen; Peter Andersen; Aase B Andersen
Journal:  PLoS One       Date:  2010-06-25       Impact factor: 3.240

8.  Diagnosis of latent tuberculosis: Can we do better?

Authors:  Ibrahim O Al-Orainey
Journal:  Ann Thorac Med       Date:  2009-01       Impact factor: 2.219

9.  Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose.

Authors:  Claus Aagaard; Truc Thi Kim Thanh Hoang; Angelo Izzo; Rolf Billeskov; JoLynn Troudt; Kim Arnett; Andrew Keyser; Tara Elvang; Peter Andersen; Jes Dietrich
Journal:  PLoS One       Date:  2009-06-16       Impact factor: 3.240

10.  Evaluation of interferon-gamma release assays in the diagnosis of recent tuberculosis infection in health care workers.

Authors:  Irma Casas; Irene Latorre; Maria Esteve; Juan Ruiz-Manzano; Dora Rodriguez; Cristina Prat; Ignasi García-Olivé; Alicia Lacoma; Vicente Ausina; Jose Domínguez
Journal:  PLoS One       Date:  2009-08-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.